EXAS – exact sciences corporation (US:NASDAQ)

News

Exact Sciences to Participate in J.P. Morgan Healthcare Conference
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Bank of America Co. from $75.00 to $72.00. They now have a "buy" rating on the stock.
Bladder Cancer Detection Kit Market to Hit USD 2.99 Billion by 2032, Driven by Advancements in Non-Invasive Technologies | Research by SNS Insider [Yahoo! Finance]
AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates [Yahoo! Finance]
Exploring High Growth Tech Stocks in December 2024 [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com